Vivera Pharmaceuticals Licenses TABMELT®, a Sublingual Pharmaceutical Drug-Delivery System for Cannabidiol (CBD)

Company to focus on benefits of CBD for non-addictive pain management
and opioid, alcohol addiction recovery

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CBD?src=hash” target=”_blank”gt;#CBDlt;/agt;–Vivera
Pharmaceuticals, Inc., a pharmaceutical company focused on
non-addictive pain management, today announces the debut of TABMELT®, a
sublingual drug delivery system that Vivera has exclusively licensed for
the specific use for pharmaceutical cannabinoids, including cannabidiol
(CBD), a non-psychoactive compound derived from hemp, and other
hemp-derived and biosynthetic cannabinoid compounds.

“According to the Centers for Disease Control and Prevention, on
average, 130 Americans die every single day from an opioid overdose,”
said Dr. Jon Norman, Chief Scientific Officer at Vivera. “We believe CBD
has several important roles to play in this national crisis. It may
offer a non-addictive way to manage pain and may create an alternative
to starting patients on opioids in the first place. In addition, it may
hold promise as a way to ease the detox process for patients in drug or
alcohol recovery.”

Internationally patented and U.S. patent-pending TABMELT® may optimize
the pharmaceutical delivery of CBD by offering a sublingual, set-dose
system, which may enhance bioavailability by largely avoiding first-pass
metabolism through the liver.

“Vivera’s commitment to innovative research, product development, and
providing non-addictive therapies and treatments to patients is the
foundation of our work,” said Olivia Karpinski, Co-founder and Executive
Vice President of Vivera. “Our goal is to provide a non-addictive
solution to patients nationwide who seek to manage pain and opioid
cessation and deterrence in a safer way.”

Vivera is headquartered in Newport Beach, California.

For more information, visit https://viverapharma.com.

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven
pharmaceutical company focused on opioid deterrence and cessation and
non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the
company has global exclusivity to license the patented and
patent-pending TABMELT® sublingual drug-delivery system for the
pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical
trials on CBD in the TABMELT® drug delivery format with the goal of
gaining FDA approval for its products.

The company is vertically integrated with patented technology,
manufacturing capabilities and distribution for its products.

For more information, visit https://viverapharma.com.

Forward-looking and cautionary statements:

The securities described herein, if any, have not been, and will not be,
registered under the United States Securities Act of 1933, as amended
(the “U.S. Securities Act”), or any state securities laws, and may not
be offered or sold within the United States or to, or for the benefit
of, U.S. persons (as defined in Regulation S under the U.S. Securities
Act) except in compliance with the registration requirements of the U.S.
Securities Act and applicable state securities laws or pursuant to
exemptions therefrom. This release does not constitute an offer to sell
or a solicitation of an offer to buy of any of Vivera Pharmaceuticals
securities in the United States. This news release may contain
“forward-looking information” as defined in applicable Canadian
securities legislation. All statements other than statements of
historical fact included in this release, including, without limitation,
future operating margins, future production and processing, processing
results, and future plans and objectives of Vivera Pharmaceuticals,
constitute forward looking information that involve various risks and
uncertainties. Forward-looking information is based on a number of
factors and assumptions which have been used to develop such information
but which may prove to be incorrect, including, but not limited to,
assumptions in connection with the continuance of Vivera Pharmaceuticals
and its subsidiaries as a going concern, general economic and market
conditions, price of biomass, the accuracy of production resource
estimates, and the performance of Vivera Pharmaceuticals future
operations. There can be no assurance that such information will prove
to be accurate and actual results and future events could differ
materially from those anticipated in such forward-looking information.
Important factors that could cause actual results to differ materially
from Vivera Pharmaceuticals’ expectations include but are not limited
to: changes in economic conditions or financial markets; increases in
costs; litigation; legislative, environmental and other judicial,
regulatory, political and competitive developments; and technological or
operational difficulties. This list is not exhaustive of the factors
that may affect our forward-looking information. These and other factors
should be considered carefully, and readers should not place undue
reliance on such forward-looking information. For additional information
with respect to risk factors applicable to Vivera Pharmaceuticals,
reference should be made to Vivera Pharmaceuticals continuous disclosure
materials filed from time to time with securities regulators, including,
but not limited to, Vivera Pharmaceuticals CSE Listing Statement. The
forward-looking information contained in this release is made as of the
date of this release. Vivera Pharmaceuticals does not intend, and
expressly disclaims any intention or obligation to update or revise any
forward-looking information whether as a result of new information,
future events or otherwise, except as required by applicable law. The
CSE has not reviewed, approved or disapproved the contents of this press
release.

Contacts

Investor Relations and Canadian Media Enquiries:
ThinkHERO
Patrick
Piette, CFA for Vivera Pharmaceuticals, Inc.
416-526-9911
investorrelations@viverapharma.com

U.S. Media Inquiries:
SRPR
Brenda Patterson for Vivera
Pharmaceuticals, Inc.
949-667-1943
press@viverapharma.com